iBionext

iBionext originates most deals through proprietary relationships with French public research institutions including INSERM, CNRS, and major universities. The firm's team identifies promising scientific work before company formation, then assembles founding teams and intellectual property frameworks around those discoveries. This embedded sourcing model gives iBionext access to lab-stage projects that never reach open fundraising processes.

The firm focuses on pre-seed and seed stages, typically leading initial rounds between €500,000 and €3 million for newly formed health-tech companies. iBionext maintains reserves for follow-on participation through Series A and B, particularly when its portfolio companies hit preclinical proof-of-concept or early clinical milestones. The commitment horizon for each portfolio position is typically 7–10 years.

iBionext's limited partners have not been publicly disclosed in detail, though French institutional investors and European life-science-focused funds of funds are typical capital sources for vehicles of this profile. Bpifrance, the French public investment bank, has co-invested alongside iBionext in portfolio companies, indicating some indirect public-sector capital alignment without direct LP disclosure.

The firm's primary origination remains French academic and hospital systems, but iBionext has backed companies with pan-European operations. LynxCare, for example, is headquartered in Belgium and serves hospital networks across the EU. The firm will syndicate internationally when a portfolio company's clinical development pathway requires US or broader European co-investors.

iBionext functions as a venture studio for health-tech: it identifies academic research, creates companies around that research, and operates them through earliest-stage development before handing operational control to recruited management teams. This model means iBionext carries higher company-formation costs and deeper scientific due-diligence burdens than a fund evaluating external decks, but it captures proprietary deal flow that never reaches open markets.